ClinicalTrials.gg
Enrolling by invitationNCT06529042SCRIPTUpdated Nov 27, 2024

SCRIPT: Sickle Cell Risk in Pregnancy Tool

An observational study in Sickle Cell Disease, Pregnancy, High Risk and Pregnancy Complications, sponsored by Mount Sinai Hospital, Canada. Enrolling by invitation at 3 sites in 2 countries. Open to female participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by Mount Sinai Hospital, Canada · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
16 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 55 studies in Anemia, Sickle Cell with a site in Canada — 15 open to participants now, 22 under way, 7 of them phase 3. Anemia, Sickle Cell · Canada.

Started
2024
with 4 others
Observational
5 of 55
4 open now
Primary completion
2026-12
later than 9 of 21 live
Registered
49th of 55
by date

Among the 55 studies in Anemia, Sickle Cell with a site in Canada, this one is one of 5 that started in 2024, is one of 5 observational ones, reaches primary completion later than 9 of the 21 other live ones, and was the 49th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

15 of the 55 studies in Anemia, Sickle Cell with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 16 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Anemia, Sickle Cell with a site in Canada, or all of them as a file.
02

Study summary

Sickle Cell Disease (SCD), common in persons of Black ancestry, affects the shape of hemoglobin, the oxygen-carrying part of red blood cells (RBC). It is characterized by many complications, the most dreaded of which are related to pregnancy - affecting both the mother and unborn child. Compared to those without SCD, people with SCD have more adverse pregnancy outcomes (APO): 6x maternal mortality, 2x preeclampsia \& preterm birth, 4x risk of having a baby not growing well in the womb \& stillbirth. There is also greater need for access to care (7x higher hospitalization often multiple times lasting days to months). Yet up to 30% of SCD pregnancies are uncomplicated.

Treatments in pregnancy are limited and carry risks. A method to distinguish pregnancies at high-risk of APO that may benefit from these potentially risky treatments, from those likely to be uncomplicated, is urgently needed. To meet this need, the investigators developed a calculator to estimate pregnancy complication risk, using single-centre data. Its accuracy and precision will now be evaluated with international information from several centers by testing the calculator, and adjusting it as needed, using already available pregnancy-data from study centres in several countries. Those age >16 years, who have a confirmed SCD genotype, pregnancy with one baby, and pregnancy care and birth at a participating study centre will be included. Pregnancy care for the participants will be up to their doctors, with no changes based on the study. SCRIPT - the new tool - will guide future care by predicting who may benefit from specific treatments, reducing harm to low-risk individuals \& will allow selection of high-risk patients for a future trials to determine whether currently available and novel treatments in well-selected patients can improve APO sufficiently to balance treatment-related harms.

Read the detailed description

Sickle Cell Disease (SCD) is the most common haemoglobinopathy; predominantly affecting persons of African descent(1). In comparison to those without SCD, pregnant persons with SCD have a six-fold higher risk of mortality, twice the risk of preeclampsia and preterm birth, and nearly a four-fold risk of having a small for gestational age infant or experiencing stillbirth(2,3). Furthermore, there is a higher rate of resource utilization in this group, with nearly 50% of pregnancies complicated by at least one antenatal admission and an overall seven-fold higher hospitalization risk compared to pregnancies without SCD(4,5). These admissions are most commonly secondary to vaso-occlusive events or anemia, can occur on multiple occasions, and can last days to months(4,5).

During pregnancy, red blood cell (RBC) transfusion remains the only recommended intervention(6), with some evidence suggesting that prophylactic transfusion may modify adverse pregnancy outcomes (APOs)(7,8), with a possible positive effect on hospitalization rates through decreased complications, though this requires further study. However, transfusion is not without risk. Beyond its typically-feared infectious complications(9), transfusion in SCD is associated with alloimmunization rates of over 30%(10-12), can induce life-threatening hyperhemolysis(13), and will eventually lead to iron overload(14). At the same time, up to 30% of pregnancies in individuals with SCD remain uncomplicated(2,3,15,16).

A tool is thus urgently needed to separate high-risk individuals who would benefit from transfusion from low-risk individuals who would accrue transfusion risks with minimal, if any benefit. Using a single-centre cohort, the investigators developed maternal and fetal risk prediction models, as the first step in permitting the selection of patients most likely to benefit from transfusion(16). Ultimately, a multi-center international randomized controlled trial (RCT) is required to determine the benefits of prophylactic transfusion in this setting; yet, before such an RCT is conceived, the model(s) must be refined and validated with a larger sample to allow for appropriate participant selection.

The investigators proposed a multicenter international cohort study to enhance the predictive capacity and validate the current model(s) within the participating centers. The academic centers (located in Canada, USA, and France), have multi-disciplinary experts dedicated to managing pregnant persons with SCD, and the combination of MFM and Haematology site co-leads provides essential interdisciplinary expertise with synergistic medical and obstetric perspectives.

Once completed, the Sickle Cell Risk In Pregnancy Tool (SCRIPT) will inform medical decisions regarding transfusion and will set the stage for appropriate selection of high-risk individuals for inclusion in an RCT aimed to definitively determine whether prophylactic transfusion in well-selected pregnant individuals with SCD does indeed improve APOs to the degree that would balance its potential associated harms.

03

Conditions studied

  • Sickle Cell Disease
  • Pregnancy, High Risk
  • Pregnancy Complications

Keywords

  • Risk Assessment
  • Bayesian Prediction
04

Who can participate

Ages eligible
16 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Pregnant Individuals with Sickle Cell Disease (HbSS, HbSC, HbS/β0-thalassemia, HbS/β+-thalassemia)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >16 years
  • HbSS, HbSC, HbS/β0-thalassemia, HbS/β+-thalassemia confirmed on electrophoresis, high performance liquid chromatography, capillary electrophoresis, or genetic testing
  • Records of pregnancy care and birth at a participating centre
  • Pregnancy continuing to at least 16+0 weeks' gestation (41,42)

Exclusion criteria

Exclusion Criteria:

  • Inability to confirm SCD genotype
  • Incomplete medical records.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pregnancies of Individuals with Sickle Cell Disease

    Other: Non-Interventional

Interventions

  • OtherNon-Interventional

    Non-Interventional

06

What researchers measure

Primary outcomes

  1. Presence of Adverse Pregnancy Outcome

    Yes, if any of the following events first noted during the pregnancy within the study period: acute anemia (yes, no), cardiac complication (yes, no), pulmonary complication (yes, no), hepatobiliary complication (yes, no), MSK complication (yes, no), splenic complication (yes, no), neurologic complication (yes, no), renal complication (yes, no); multi-organ failure (yes, no), venous thromboembolism (yes, no), vaso-occlusive event with admission (yes, no), red cell transfusion (yes, no), maternal mortality (yes, no), hypertensive disorder of pregnancy (yes, no), preterm birth (yes, no), small for gestational age (yes, no), or perinatal mortality (yes, no); defined based on published classifications.

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

Secondary outcomes

  1. Presence of Acute Anemia

    Yes, if any of: hyperhemolysis \[clinical diagnosis\], acute splenic sequestration; hepatic sequestration, or aplastic crisis; defined based on published classification

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  2. Presence of Cardiac Complications

    Yes, if any of: congestive heart failure, cardiomyopathy, cardiomegaly, or arrhythmia; defined based on published classification

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  3. Presence of Pulmonary Complications

    Yes, if any of: acute chest syndrome; pneumonia, or pulmonary hypertension; defined based on published classification

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  4. Presence of Hepato-Biliary Complications

    Yes, if any of: cholecystitis, cholelithiasis; cholecystectomy; cholestasis of pregnancy, or viral hepatitis; defined based on published classification

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  5. Presence of Musculo-Skeletal Complications

    Yes, if any of: avascular necrosis, ulcer, myositis, or osteomyelitis; defined based on published classification

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  6. Presence of Neurologic Complications

    Yes, if any of: silent cerebral infarct, cerebrovascular accident, cerebral aneurysm, transient ischemic attack, or Moya-Moya syndrome; defined based on published classification

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  7. Presence of Renal Complications

    Yes, if any of: acute kidney injury, proteinuria, pyelonephritis, or hematuria; defined based on published classification

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  8. Presence of Multi-Organ Failure

    Consultant's opinion in chart note specifying a diagnosis of "MOF" during current study pregnancy; clinical diagnosis

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  9. Presence of Venous Thromboembolism

    Yes, if any of: deep vein thrombosis, pulmonary embolism, atypical site venous thrombosis, or cerebral venous sinus thrombosis (CVST); defined based on published classification

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  10. Presence of Vaso-Occlusive Event with Admission

    Vaso-Occlusive Event (VOE): New onset pain lasting \>4 hrs in current study pregnancy, for which there is no explanation other than vaso-occlusion, and which requires presentation for acute care - patient self-report

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  11. Provision of Red Blood Cell Transfusion

    Yes, if any of: simple transfusion in pregnancy, exchange transfusion (manual exchange or erythrocytapheresis), or prophylactic transfusion

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  12. Occurrence of Maternal Mortality

    Maternal death during current study pregnancy and up to 6 months postpartum

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation) and continuing to 6 months postpartum

  13. Presence of Hypertensive Disorder of Pregnancy

    Yes, if any of: Gestational Hypertension (gHTN) \[persistent de novo HTN over 20 weeks' GA in absence of features of preeclampsia\], Pre-eclampsia (PET) \[gHTN + \>1 new onset conditions \>20 weeks GA - proteinuria or maternal organ/uteroplacental dysfunction\], Eclampsia \[new onset seizures in context of pre-eclampsia\]; or HELLP Syndrome \[Evidence of Hemolysis, Elevated Liver Enzymes, Low Platelets in context of pre-eclampsia\]

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  14. Occurrence of Preterm Birth

    Preterm birth (\< 37+0 weeks GA) during current study pregnancy

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)

  15. Presence of Small for Gestational Age (SGA) Size

    Birthweight \<10th centile for gestational age

    Time frame: At delivery of infant

  16. Occurrence of Perinatal Mortality

    Intrauterine fetal demise (IUFD) \[absence of FHR at or after 20 weeks' gestation\] or Neonatal Death (NND) \[death before 28 days of life, following live birth\]

    Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation) and up to 28 days after birth)

07

Study locations

3 sites
08

References and documents

Publications

  • Boafor TK, Olayemi E, Galadanci N, Hayfron-Benjamin C, Dei-Adomakoh Y, Segbefia C, Kassim AA, Aliyu MH, Galadanci H, Tuuli MG, Rodeghier M, DeBaun MR, Oppong SA. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG. 2016 Apr;123(5):691-8. doi: 10.1111/1471-0528.13786. Epub 2015 Dec 15. PubMed 26667608 ↗
  • Oteng-Ntim E, Meeks D, Seed PT, Webster L, Howard J, Doyle P, Chappell LC. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood. 2015 May 21;125(21):3316-25. doi: 10.1182/blood-2014-11-607317. Epub 2015 Mar 23. PubMed 25800049 ↗
  • Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol. 2001 May;184(6):1127-30. doi: 10.1067/mob.2001.115477. PubMed 11349177 ↗
  • Yu CK, Stasiowska E, Stephens A, Awogbade M, Davies A. Outcome of pregnancy in sickle cell disease patients attending a combined obstetric and haematology clinic. J Obstet Gynaecol. 2009 Aug;29(6):512-6. doi: 10.1080/01443610903003175. PubMed 19697199 ↗
  • Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J, Kameka M, Kwiatkowski JL, Pirenne F, Shi PA, Stowell SR, Thein SL, Westhoff CM, Wong TE, Akl EA. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020 Jan 28;4(2):327-355. doi: 10.1182/bloodadvances.2019001143. PubMed 31985807 ↗
  • Malinowski AK, Shehata N, D'Souza R, Kuo KH, Ward R, Shah PS, Murphy K. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood. 2015 Nov 19;126(21):2424-35; quiz 2437. doi: 10.1182/blood-2015-06-649319. Epub 2015 Aug 24. PubMed 26302758 ↗
  • Vianello A, Vencato E, Cantini M, Zanconato G, Manfrin E, Zamo A, Zorzi F, Mazzi F, Martinelli N, Cavaliere E, Monari F, Venturelli D, Ferrara F, Olivieri O, De Franceschi L. Improvement of maternal and fetal outcomes in women with sickle cell disease treated with early prophylactic erythrocytapheresis. Transfusion. 2018 Sep;58(9):2192-2201. doi: 10.1111/trf.14767. Epub 2018 Jul 8. PubMed 29984534 ↗
  • Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2013;2013:439-46. doi: 10.1182/asheducation-2013.1.439. PubMed 24319217 ↗
  • Kacker S, Ness PM, Savage WJ, Frick KD, Shirey RS, King KE, Tobian AA. Economic evaluation of a hypothetical screening assay for alloimmunization risk among transfused patients with sickle cell disease. Transfusion. 2014 Aug;54(8):2034-44. doi: 10.1111/trf.12585. Epub 2014 Feb 27. PubMed 24571485 ↗
  • Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012 Jul 19;120(3):528-37. doi: 10.1182/blood-2011-11-327361. Epub 2012 May 4. PubMed 22563085 ↗
  • Balbuena-Merle R, Hendrickson JE. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Transfus Clin Biol. 2019 May;26(2):112-115. doi: 10.1016/j.tracli.2019.02.003. Epub 2019 Feb 22. PubMed 30857806 ↗
  • Danaee A, Inusa B, Howard J, Robinson S. Hyperhemolysis in Patients With Hemoglobinopathies: A Single-Center Experience and Review of the Literature. Transfus Med Rev. 2015 Oct;29(4):220-30. doi: 10.1016/j.tmrv.2015.06.001. Epub 2015 Jun 19. PubMed 26209603 ↗
  • Tavares AHJ, Benites BD, Fertrin KY. Myocardial Iron Overload in Sickle Cell Disease: A Rare But Potentially Fatal Complication of Transfusion. Transfus Med Rev. 2019 Jul;33(3):170-175. doi: 10.1016/j.tmrv.2019.04.001. Epub 2019 May 2. PubMed 31153715 ↗
  • Silva FAC, Ferreira ALCG, Hazin-Costa MF, Dias MLG, Araujo AS, Souza AI. Adverse clinical and obstetric outcomes among pregnant women with different sickle cell disease genotypes. Int J Gynaecol Obstet. 2018 Oct;143(1):89-93. doi: 10.1002/ijgo.12626. Epub 2018 Aug 6. PubMed 30030929 ↗
  • Malinowski AK, Kuo KHM, Tomlinson GA, Palcu P, Ward R, Shehata N. Distinct maternal and fetal pregnancy outcomes in women with sickle cell disease can be predicted using routine clinical and laboratory data. Br J Haematol. 2021 Sep;194(6):1063-1073. doi: 10.1111/bjh.17607. Epub 2021 Jun 14. PubMed 34124774 ↗
  • Odendaal H, Wright C, Brink L, Schubert P, Geldenhuys E, Groenewald C. Association of late second trimester miscarriages with placental histology and autopsy findings. Eur J Obstet Gynecol Reprod Biol. 2019 Dec;243:32-35. doi: 10.1016/j.ejogrb.2019.10.024. Epub 2019 Oct 22. PubMed 31670146 ↗
  • Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2013 May;41(5):491-9. doi: 10.1002/uog.12421. PubMed 23362106 ↗
  • Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, Johnson CS, Rogers ZR, Smith-Whitley K, Wang WC, Telen MJ; Investigators, Comprehensive Sickle Cell Centers. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010 Jan;85(1):6-13. doi: 10.1002/ajh.21550. PubMed 19902523 ↗
  • Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014 May;36(5):416-41. doi: 10.1016/s1701-2163(15)30588-0. English, French. PubMed 24927294 ↗
  • Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, Blondel B, Breart G; Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001 Aug;108(2):E35. doi: 10.1542/peds.108.2.e35. PubMed 11483845 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 31, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06529042
Collaborators
Johns Hopkins University, Centre hospitalier de l'Université de Montréal (CHUM), St. Paul's Hospital, Vancouver (Providence Health Care)
Responsible party
Sponsor
First posted
Jul 31, 2024
Start date
Sep 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 27, 2024

Study contacts

A. Kinga Malinowski, MD, MSc
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion